⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370514 | 0.67 | — | — | |
| SCHEMBL367986 | 0.67 | — | — | |
| SCHEMBL8131237 | 0.59 | — | — | |
| SCHEMBL38028 | 0.59 | — | — | |
| SCHEMBL66538 | 0.59 | — | — | |
| SCHEMBL3434947 | 0.59 | — | — | |
| SCHEMBL499165 | 0.59 | — | — | |
| SCHEMBL15948266 | 0.59 | — | — | |
| SCHEMBL499166 | 0.59 | — | — | |
| SCHEMBL83540 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844660-B1 | TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RES INST (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2015184222-A1 | INHIBITORS OF HEPATOCYTE GROWTH FACTOR [HGF] AND MACROPHAGE STIMULATING PROTEIN [MSP] MATURATION | SOUTHERN RESEARCH INSTITUTE (US) | 2015-12-03 | — | — | WO | disclosed |
| EP-2844660-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | Southern Research Institute (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013166276-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2013-11-07 | — | — | WO | disclosed |
| WO-1995001396-A1 | SOIL RESISTANT FIBERS | PEACH STATE LABS, INC. (US) | 1995-01-12 | — | — | WO | disclosed |